Related references
Note: Only part of the references are listed.Lymphocytic colitis associated with entacapone
David M. Rodrigues et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial
Eduardo Tolosa et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone
David J. Graham et al.
MOVEMENT DISORDERS (2013)
The COMT Val158Met Polymorphism Affects the Response to Entacapone in Parkinson's Disease: A Randomized Crossover Clinical Trial
Jean-Christophe Corvol et al.
ANNALS OF NEUROLOGY (2011)
Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease The STRIDE-PD Study
Fabrizio Stocchi et al.
ANNALS OF NEUROLOGY (2010)
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis
H. Nissinen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Quality of Life in Early Parkinson's Disease Treated with Levodopa/Carbidopa/Entacapone
Victor S. C. Fung et al.
MOVEMENT DISORDERS (2009)
Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2009)
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease
David J. Brooks et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2007)
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations
H Reichmann et al.
ACTA NEUROLOGICA SCANDINAVICA (2005)
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
DJ Brooks et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2003)
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations.: A randomized, double-blind, multicentre study
G Fénelon et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)
WH Poewe et al.
ACTA NEUROLOGICA SCANDINAVICA (2002)
Twelve-month safety of entacapone in patients with Parkinson's disease
VV Myllyla et al.
EUROPEAN JOURNAL OF NEUROLOGY (2001)
Share Paper
